<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Phenobarbital</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01174</strong>&#160; (APRD00184)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01174/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01174/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01174.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01174.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01174.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01174.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01174.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01174">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>5-Ethyl-5-phenyl-pyrimidine-2,4,6-trione</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>5-Ethyl-5-phenylbarbituric acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>5-ethyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>5-Phenyl-5-ethylbarbituric acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Phenobarbitol</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Phenobarbitone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Phenobarbituric Acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Phenylethylbarbiturate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Phenylethylbarbituric Acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Luminal</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/hypnotics-and-sedatives">Hypnotics and Sedatives</a></li>
<li><a href="/mesh/anticonvulsants">Anticonvulsants</a></li>
<li><a href="/mesh/gaba-modulators">GABA Modulators</a></li>
<li><a href="/mesh/excitatory-amino-acid-antagonists">Excitatory Amino Acid Antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>50-06-6</td></tr><tr><th>Weight</th><td>Average: 232.2353<br>Monoisotopic: 232.08479226</td></tr><tr><th>Chemical Formula</th><td>C<sub>12</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub></td></tr><tr><th>InChI Key</th><td>DDBREPKUVSBGFI-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB01174.gif?1265922774">show</a>(8.44 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Diazines</td></tr><tr><th>Subclass</th><td>Pyrimidines and Pyrimidine Derivatives</td></tr><tr><th>Direct parent</th><td>Barbituric Acid Derivatives</td></tr><tr><th>Alternative parents</th><td>Ureides; Diazinanes; Benzene and Substituted Derivatives; N-unsubstituted Carboxylic Acid Imides; Secondary Carboxylic Acid Amides; Carboxylic Acids; Polyamines</td></tr><tr><th>Substituents</th><td>ureide; 1,3-diazinane; benzene; carboxylic acid imide, n-unsubstituted; carboxamide group; secondary carboxylic acid amide; carboxylic acid derivative; polyamine; carboxylic acid; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of all types of seizures except absence seizures.</td></tr><tr><th>Pharmacodynamics</th><td>Phenobarbital, the longest-acting barbiturate, is used for its anticonvulsant and sedative-hypnotic properties in the management of all seizure disorders except absence (petit mal).</td></tr><tr><th>Mechanism of action</th><td>Phenobarbital acts on GABAA receptors, increasing synaptic inhibition. This has the effect of elevating seizure threshold and reducing the spread of seizure activity from a seizure focus. Phenobarbital may also inhibit calcium channels, resulting in a decrease in excitatory transmitter release. The sedative-hypnotic effects of phenobarbital are likely the result of its effect on the polysynaptic midbrain reticular formation, which controls CNS arousal.</td></tr><tr><th>Absorption</th><td>Absorbed in varying degrees following oral, rectal or parenteral administration. The salts are more rapidly absorbed than are the acids. The rate of absorption is increased if the sodium salt is ingested as a dilute solution or taken on an empty stomach.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>20 to 45%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic (mostly via CYP2C19).</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Phenobarbital</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET00111">p-Hydroxyphenobarbital</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/111">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00111">p-Hydroxyphenobarbital</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01217">Phenobarbital O-sulfate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1364">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00111">p-Hydroxyphenobarbital</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01218">Phenobarbital O-glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1365">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>53 to 118 hours (mean 79 hours)</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>CNS and respiratory depression which may progress to Cheyne-Stokes respiration, areflexia, constriction of the pupils to a slight degree (though in severe poisoning they may wshow paralytic dilation), oliguria, tachycardia, hypotension, lowered body temperature, and coma. Typical shock syndrome (apnea, circulatory collapse, respiratory arrest, and death) may occur.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9935</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9736</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5561</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5157</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6472</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9869</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9235</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.6962</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7702</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.84</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9023</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9593</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8664</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9236</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9164</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.9107
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7469
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9894
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.1244 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.99
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9354
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.actavis.com">Actavis Group</a></li>
<li>Amend</li>
<li>Apotheca Inc.</li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.bpirx.com">Breckenridge Pharmaceuticals</a></li>
<li>C.O. Truxton Inc.</li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Carlisle Laboratories Inc.</li>
<li><a href="http://www.dakins.net">Century Pharmaceuticals Inc.</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.econo-lab.com">Econolab Inc.</a></li>
<li><a href="http://www.excellium.com">Excellium Pharmaceutical Inc.</a></li>
<li><a href="http://www.ghc.org">Group Health Cooperative</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.hikma.com">Hikma Pharmaceuticals</a></li>
<li>Hl Moore Drug Exchange</li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li>Kaiser Foundation Hospital</li>
<li>Kraft Pharmaceutical Co. Inc.</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.lundbeckinc.com">Lundbeck Inc.</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mallinckrodt.com">Mallinckrodt Inc.</a></li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.ohmlabs.com">Ohm Laboratories Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li>Pharmaceutical Association</li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li>Pharmacy Service Center</li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.riversedgepharma.com">River's Edge Pharmaceuticals</a></li>
<li><a href="http://www.stanleypharma.com">Stanley Pharmaceuticals Ltd.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li><a href="http://www.urlpharma.com">United Research Laboratories Inc.</a></li>
<li>Vintage Pharmaceuticals Inc.</li>
<li><a href="http://www.west-ward.com">West-Ward Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Elixir</td><td>Oral</td><td></td></tr><tr><td>Solution</td><td>Intramuscular</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB05812">Abiraterone</a></td><td>Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The barbiturate, phenobarbital, decreases the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>The barbiturate, phenobarbital, decreases the effect of aminophylline.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>The barbiturate, phenobarbital, decreases the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB06216">Asenapine</a></td><td>Phenobarbital is a CYP1A2 inducer and may increase metabolism of asenapine. </td></tr><tr><td><a href="/drugs/DB06769">Bendamustine</a></td><td>Increases levels of bendamustine by decreasing metabolism. Ethinyl Estradiol is a CYP1A2 inhibitor and concurrent administration may result in elevated plasma concentrations of bendamustine. </td></tr><tr><td><a href="/drugs/DB00443">Betamethasone</a></td><td>The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, betamethasone.</td></tr><tr><td><a href="/drugs/DB08873">Boceprevir</a></td><td>Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB06772">Cabazitaxel</a></td><td>Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy. </td></tr><tr><td><a href="/drugs/DB08907">Canagliflozin</a></td><td>Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily. </td></tr><tr><td><a href="/drugs/DB00269">Chlorotrianisene</a></td><td>The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, chlorotrianisene.</td></tr><tr><td><a href="/drugs/DB00882">Clomifene</a></td><td>The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB00286">Conjugated Estrogens</a></td><td>The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, conjugated estrogens.</td></tr><tr><td><a href="/drugs/DB01380">Cortisone acetate</a></td><td>The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, cortisone acetate.</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>The barbiturate, phenobarbital, may decrease the therapeutic effect of cyclosporine by increasing its metabolism.</td></tr><tr><td><a href="/drugs/DB08912">Dabrafenib</a></td><td>Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB01254">Dasatinib</a></td><td>Phenobarbital may decrease the serum level and efficacy of dasatinib.</td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>The anticonvulsant, phenobarbital, decreases the effect of delavirdine.</td></tr><tr><td><a href="/drugs/DB01234">Dexamethasone</a></td><td>The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, dexamethasone.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>The barbiturate, phenobarbital, decreases the anticoagulant effect, dicumarol.</td></tr><tr><td><a href="/drugs/DB00255">Diethylstilbestrol</a></td><td>The enzyme inducer, phenobarbital, may decrease the therapeutic effect of diethylstilbestrol.</td></tr><tr><td><a href="/drugs/DB00280">Disopyramide</a></td><td>Phenobarbital decreases levels of disopyramide</td></tr><tr><td><a href="/drugs/DB00254">Doxycycline</a></td><td>The anticonvulsant, phenobarbital, may decrease the therapeutic effect of doxycycline.</td></tr><tr><td><a href="/drugs/DB00651">Dyphylline</a></td><td>The barbiturate, phenobarbital, decreases the effect of dyphylline.</td></tr><tr><td><a href="/drugs/DB00783">Estradiol</a></td><td>The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estradiol.</td></tr><tr><td><a href="/drugs/DB08866">Estradiol valerate/Dienogest</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB04573">Estriol</a></td><td>The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estriol.</td></tr><tr><td><a href="/drugs/DB00655">Estrone</a></td><td>The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estrone.</td></tr><tr><td><a href="/drugs/DB04574">Estropipate</a></td><td>The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estropipate.</td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Etravirine, when used concomitantly with phenobarbital, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.</td></tr><tr><td><a href="/drugs/DB00949">Felbamate</a></td><td>Felbamate increases the effect and toxicity of phenobarbital/primidone</td></tr><tr><td><a href="/drugs/DB01023">Felodipine</a></td><td>The barbiturate, phenobarbital, decreases the effect of felodipine.</td></tr><tr><td><a href="/drugs/DB00687">Fludrocortisone</a></td><td>The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB00158">Folic Acid</a></td><td>Folic acid decreases the effect of anticonvulsant, phenobarbital.</td></tr><tr><td><a href="/drugs/DB00317">Gefitinib</a></td><td>The CYP3A4 inducer, phenobarbital, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB00400">Griseofulvin</a></td><td>The barbiturate, phenobarbital, decreases the effect of griseofulvin.</td></tr><tr><td><a href="/drugs/DB00741">Hydrocortisone</a></td><td>The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, hydrocortisone.</td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>Phenobarbital decreases levels of imatinib</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>The barbiturate, phenobarbital, decreases the effect of itraconazole.</td></tr><tr><td><a href="/drugs/DB08820">Ivacaftor</a></td><td>Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00367">Levonorgestrel</a></td><td>Phenobarbital decreases the effect of levonorgestrel</td></tr><tr><td><a href="/drugs/DB00603">Medroxyprogesterone Acetate</a></td><td>The enzyme inducer, phenobarbital, may decrease the effect of the hormone, medroxyprogesterone.</td></tr><tr><td><a href="/drugs/DB00351">Megestrol acetate</a></td><td>The enzyme inducer, phenobarbital, may decrease the effect of the hormone, megestrol.</td></tr><tr><td><a href="/drugs/DB01357">Mestranol</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB00333">Methadone</a></td><td>The barbiturate, phenobarbital, decreases the effect of methadone.</td></tr><tr><td><a href="/drugs/DB01028">Methoxyflurane</a></td><td>The barbiturate, phenobarbital, increases the renal toxicity of methoxyflurane.</td></tr><tr><td><a href="/drugs/DB00959">Methylprednisolone</a></td><td>The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, methylprednisolone.</td></tr><tr><td><a href="/drugs/DB00264">Metoprolol</a></td><td>The barbiturate decreases the effect of the metabolized beta-blocker</td></tr><tr><td><a href="/drugs/DB00916">Metronidazole</a></td><td>The barbiturate, phenobarbital, decreases the effect of metronidazole.</td></tr><tr><td><a href="/drugs/DB01115">Nifedipine</a></td><td>The barbiturate, phenobarbital, may decrease the effect of the calcium channel blocker, nifedipine.</td></tr><tr><td><a href="/drugs/DB00717">Norethindrone</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>The barbiturate, phenobarbital, decreases the effect of oxtriphylline.</td></tr><tr><td><a href="/drugs/DB01384">Paramethasone</a></td><td>The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, paramethasone.</td></tr><tr><td><a href="/drugs/DB00860">Prednisolone</a></td><td>The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, prednisolone.</td></tr><tr><td><a href="/drugs/DB00635">Prednisone</a></td><td>The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, prednisone.</td></tr><tr><td><a href="/drugs/DB00571">Propranolol</a></td><td>The barbiturate decreases the effect of the metabolized beta-blocker</td></tr><tr><td><a href="/drugs/DB04575">Quinestrol</a></td><td>The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, quinestrol.</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>The anticonvulsant, phenobarbital, decreases the effect of quinidine.</td></tr><tr><td><a href="/drugs/DB08896">Regorafenib</a></td><td>Strong CYP3A4 inducers may decrease levels of regorafenib. </td></tr><tr><td><a href="/drugs/DB08864">Rilpivirine</a></td><td>Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy. </td></tr><tr><td><a href="/drugs/DB01656">Roflumilast</a></td><td>Affects CYP3A4 metabolism, decreases level or effect of roflumilast. Also decreases the level or effect of roflumilast by affecting CYP1A2 metabolism. </td></tr><tr><td><a href="/drugs/DB06201">Rufinamide</a></td><td>Increases clearance of rufinamide thus decreasing plasma concentration of rufinamide.</td></tr><tr><td><a href="/drugs/DB01268">Sunitinib</a></td><td>Possible decrease in sunitinib levels</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Phenobarbital may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Phenobarbital therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Phenobarbital may decrease the plasma concentration of Telithromycin. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Phenobarbital may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>The barbiturate, phenobarbital, decreases the effect of theophylline.</td></tr><tr><td><a href="/drugs/DB00208">Ticlopidine</a></td><td>Ticlopidine may decrease the metabolism and clearance of Phenobarbital. Consider alternate therapy or monitor for adverse/toxic effects of Phenobarbital if Ticlopidine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Phenobarbial decreases the concentration of Tipranavir. Monitor for decreased Tipranavir efficacy.</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Phenobarbital may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inducer, Phenobarbital, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Phenobarbital is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00755">Tretinoin</a></td><td>The strong CYP2C8 inducer, Phenobarbital, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Phenobarbital is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00620">Triamcinolone</a></td><td>The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, triamcinolone.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>The barbiturate, Phenobarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Phenobarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required. </td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Phenobarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB08867">Ulipristal</a></td><td>Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy. </td></tr><tr><td><a href="/drugs/DB05294">Vandetanib</a></td><td>Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  </td></tr><tr><td><a href="/drugs/DB08881">Vemurafenib</a></td><td>Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Phenobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Phenobarbital is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01080">Vigabatrin</a></td><td>Vigabatrin reduces serum concentrations of phenobarbital by 8-16%. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Phenobarbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Phenobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if phenobarbital is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Avoid excessive quantities of coffee or tea (Caffeine).</li>
<li>Increase dietary intake of magnesium, folate, vitamin B6, B12, and/or consider taking a multivitamin.</li>
<li>Take on an empty stomach for quicker absorption</li></ul></td></tr></tbody></table>